Morgan Cheatham (@morgancheatham) 's Twitter Profile
Morgan Cheatham

@morgancheatham

investing in bio, healthcare, AI @bessemervp | incoming genomics resident @harvard @bostonchildrens | editorial @NEJM_AI @decodingbio | bayesian, he/him

ID: 785805552928509953

linkhttp://morgancheatham.substack.com calendar_today11-10-2016 11:33:38

4,4K Tweet

11,11K Followers

1,1K Following

Mario Aguilar (@mariojoze) 's Twitter Profile Photo

Why this health tech investor thinks AI could bring the ‘learning health system’ to life statnews.com/2025/06/24/bre
 via STAT

Jim Breyer (@jimihendrixlive) 's Twitter Profile Photo

bit.ly/breyer-capital
 I am excited to share Breyer Capital's latest healthcare and life sciences thesis together with my partner, Morgan Cheatham, MD, our Head of Healthcare and Life Sciences.

Isaac Kohane (@zakkohane) 's Twitter Profile Photo

Most interesting part of an exciting thesis: "Prevention, which shifts care toward anticipatory systems of risk and resilience" and "...reframe prevention as a continuous, lived experience..."

Pushmeet Kohli (@pushmeet) 's Twitter Profile Photo

Happy to introduce AlphaGenome, Google DeepMind's new AI model for genomics. AlphaGenome offers a comprehensive view of the human non-coding genome by predicting the impact of DNA variations. It will deepen our understanding of disease biology and open new avenues of research.

Mustafa Suleyman (@mustafasuleyman) 's Twitter Profile Photo

We're taking a big step towards medical superintelligence. AI models have aced multiple choice medical exams – but real patients don’t come with ABC answer options. Now MAI-DxO can solve some of the world’s toughest open-ended cases with higher accuracy and lower costs.

We're taking a big step towards medical superintelligence. AI models have aced multiple choice medical exams – but real patients don’t come with ABC answer options. Now MAI-DxO can solve some of the world’s toughest open-ended cases with higher accuracy and lower costs.
Isaac Kohane (@zakkohane) 's Twitter Profile Photo

When AI “commoditizes diagnosis” we have only set the table stakes for the real game: wise and skillful clinical decision-making and management. It’s only the current decrepit state of access to human expert diagnostics that makes this first step at all compelling. HT

James Zou (@james_y_zou) 's Twitter Profile Photo

📱New conference where AI is the primary author and reviewer! agents4science.stanford.edu Current venues don't allow AI-written papers, so it's hard to assess the +/- of such worksđŸ€” #Agents4Science solicits papers where AI is the main author w/ human advisors. 💡Initial reviews by

📱New conference where AI is the primary author and reviewer! agents4science.stanford.edu

Current venues don't allow AI-written papers, so it's hard to assess the +/- of such worksđŸ€” #Agents4Science solicits papers where AI is the main author w/ human advisors.

💡Initial reviews by
Forbes (@forbes) 's Twitter Profile Photo

Daniel Nadler started OpenEvidence to help physicians sort through a deluge of medical research. Now, he’s raised $210 million at a $3.5 billion valuation. (Photo: Mauricio Candela for Forbes) trib.al/9cuLFyH

Daniel Nadler started OpenEvidence to help physicians sort through a deluge of medical research. Now, he’s raised $210 million at a $3.5 billion valuation. (Photo: Mauricio Candela for Forbes) trib.al/9cuLFyH